![]() |
市场调查报告书
商品编码
1373349
护理点凝血测试产品市场规模 - 按测试类型(凝血酶原时间测试产品、活化凝血时间 (ACT/APTT) 测试产品)、按产品类型 - 全球预测,2023-2032 年Point of Care Coagulation Testing Products Market Size - By Test Type (Prothrombin Time Testing Products, Activated Clotting Time (ACT/APTT) Testing Products), By Product Type- Global Forecast, 2023-2032 |
2023 年至 2032 年间,全球护理点凝血测试产品市场的复合年增长率将达到 7.2%。由于领先公司不断推动的合约和合作伙伴关係,该市场正在经历需求。例如,2023 年 8 月,HemoSonics (R) 是一家专门从事治疗急性出血的医疗技术的公司,从 Vizient, Inc. 获得了其 Quantra 止血系统的创新技术合约。 Quantra (R) 止血系统包括配备 QPlus (R) 和 QStat (R) 盒的 Quantra 止血分析仪,只需 15 分钟即可在护理点提供全面的全血凝固分析。 Quantra 已获得 FDA 许可,可在各种临床环境中使用,例如手术室、重症监护室和医院实验室,且维护、操作和解释的资源要求极低。
这些合作有助于开发创新产品并扩大市场范围。透过策略联盟,公司增强了自身能力,从而推出了先进的凝血测试解决方案。因此,在追求尖端技术的推动下,护理点凝血和检测产品的市场需求正在上升。
整个护理点凝血测试产品产业根据测试类型、产品类型和地区进行分类。
2023 年至 2032 年,活化凝血时间测试产品领域将经历强劲成长。这些产品在即时监测凝血方面发挥着至关重要的作用,对于手术、重症监护和管理抗凝血治疗至关重要。随着医疗保健提供者寻求有效的解决方案来改善患者的治疗结果并确保及时的临床决策,对快速、准确结果的需求正在推动护理点凝血检测产品行业的发展。
从 2023 年到 2032 年,消耗品部门将实现显着的复合年增长率。这些基本组件,包括测试盒和试剂,对于在护理点进行凝血测试至关重要。该市场的成长归因于对有助于快速凝血分析的可靠、易于使用的耗材的需求不断增加。医疗保健专业人员依靠这些产品快速提供准确的结果,因此支持他们对护理点凝血测试产品市场前景的贡献。
亚太地区护理点凝血检测产品产业从2023 年到2032 年将呈现显着的复合年增长率。这种激增可归因于人们对凝血检测重要性的认识不断增强、医疗保健基础设施的改善以及凝血障碍盛行率的上升。
对高效、便捷的凝血监测的需求推动了对这些产品的需求,最终改善整个亚太医疗保健系统的患者护理和临床结果。此外,领先的地区公司推出的即时检测产品创新数量不断增加也为市场提供了支援。例如,2023 年 1 月,总部位于孟买的製药公司 Cipla 推出了尖端的即时侦测设备 Cippoint。这种先进的设备提供了一系列全面的多种测试参数,包括凝血标记等。
Global Point of Care Coagulation Testing Products Market will witness 7.2% CAGR between 2023 and 2032. The market is experiencing demand due to the constant contracts and partnerships driven by leading companies. For instance, in August 2023, HemoSonics®, a company specializing in medical technology for managing acute bleeding, secured an Innovative Technology contract from Vizient, Inc. for its Quantra Hemostasis System. The Quantra® Hemostasis System includes the Quantra Hemostasis Analyzer equipped with QPlus® and QStat® Cartridges, delivering a comprehensive whole-blood coagulation analysis at the point of care in just 15 minutes. Quantra has received FDA clearance for usage in various clinical settings, such as operating rooms, intensive care units, and hospital laboratories, with minimal resource requirements for maintenance, operation, and interpretation.
These collaborations enable the development of innovative products and expand market reach. Through strategic alliances, companies enhance their capabilities, leading to the introduction of advanced coagulation testing solutions. As a result, the point of care coagulation and testing products market demand is on the rise, driven by the pursuit of cutting-edge technology.
The overall Point of Care Coagulation Testing Products Industry is classified based on test type, product type, and region.
Activated clotting time testing products segment will experience robust growth from 2023 to 2032. These products play a vital role in monitoring blood coagulation in real time, essential for surgeries, critical care, and managing anticoagulant therapies. The need for rapid and accurate results is driving the point of care coagulation testing products industry as healthcare providers seek efficient solutions to improve patient outcomes and ensure timely clinical decisions.
Consumables segment will register a notable CAGR from 2023 to 2032. These essential components, including test cartridges and reagents, are pivotal in conducting coagulation tests at the point of care. The market's growth is attributed to the increasing need for reliable, easy-to-use consumables that facilitate rapid coagulation analysis. Healthcare professionals rely on these products to deliver accurate results swiftly, therefore, supporting their contribution to the point of care coagulation testing products market outlook.
Asia Pacific point of care coagulation testing products industry will showcase a noteworthy CAGR from 2023 to 2032. This surge can be attributed to the growing awareness of the importance of coagulation testing, improved healthcare infrastructure, and a rising prevalence of coagulation disorders.
The demand for these products is driven by the need for efficient and accessible coagulation monitoring, ultimately enhancing patient care and clinical outcomes across Asia-Pacific healthcare systems. Additionally, the rising number of innovations in point of care testing product launches by leading regional companies also support the market. For instance, in January 2023, Cipla, a pharmaceutical company headquartered in Mumbai, unveiled Cippoint, a cutting-edge point-of-care testing device. This advanced device provides a comprehensive array of several testing parameters, including coagulation markers, among others.